Related Experiment Video
Updated: Jan 2, 2026
05:31
Transcatheter Pulmonary Valve Replacement from Autologous Pericardium with a Self-Expandable Nitinol Stent in an Adult Sheep Model
Published on: June 8, 2022
3.2K
Developments in transcatheter tricuspid valve therapies
Davide Voci1, Alberto Pozzoli1, Mizuki Miura1
1Heart Center, Zürich University Hospital, University of Zürich, Zürich, Switzerland.
Expert Review of Cardiovascular Therapy
|December 5, 2019
Summary
Transcatheter tricuspid valve (TV) procedures offer a new option for high-risk patients with severe tricuspid regurgitation. While initial results are promising, further research is needed for optimal patient selection and long-term outcomes.
Area of Science:
- Cardiology
- Interventional Cardiology
- Medical Devices
Background:
- Severe tricuspid regurgitation (TR) poses significant risks for symptomatic, high-risk patients.
- Surgical intervention for TR is associated with high morbidity and mortality.
- Transcatheter tricuspid valve (TV) procedures have emerged as a less invasive alternative.
Purpose of the Study:
- To review the current clinical evidence for transcatheter TV procedures.
- To discuss the imaging features relevant to these interventions.
- To outline the developments in transcatheter TV technologies.
Main Methods:
- A comprehensive literature search was conducted using PubMed.
- Review of existing clinical evidence and technological advancements.
- Categorization of transcatheter devices based on their mechanism of action.
Main Results:
- Transcatheter TV devices target leaflet malcoaptation, annular dilatation, or involve heterotopic implantation or complete valve replacement.
- Initial clinical experiences demonstrate encouraging outcomes.
- The field is rapidly evolving with ongoing technological innovation.
Conclusions:
- Transcatheter TV procedures represent a promising advancement for managing severe TR in high-risk patients.
- Challenges remain, including accurate patient selection and the need for long-term data.
- Future efforts should focus on early referral, robust clinical trials, and long-term outcome assessment.
Related Concept Videos
01:26Mitral Stenosis III: Medical Management
203
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
203
01:25Mitral Regurgitation III: Medical Management
229
Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
229
01:22Mitral Valve Prolapse II: Assessment and Management
328
IntroductionA range of clinical features characterizes Mitral Valve Prolapse (MVP), but it is important to note that many individuals with MVP are asymptomatic and may remain so throughout their lives. For those who do exhibit symptoms, the following are the key clinical features:Palpitations: This is a common symptom where individuals feel an irregular or rapid heartbeat. Palpitations in MVP are often due to arrhythmias such as premature ventricular contractions or supraventricular...
328
01:22Heart Failure VI: Adjunct Therapies
216
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
216
01:25Aortic Regurgitation III: Medical Management
331
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
331
01:29Venous Thrombosis III: Interprofessional Care
240
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
240